Reify Health thinks clin­i­cal tri­als can be rep­re­sen­ta­tive by 2030 — and it’s se­cured the cap­i­tal to help part­ners put in the work 

Drug de­vel­op­ers have lacked on the di­ver­si­ty front for years, es­pe­cial­ly when it comes to test­ing in­ves­ti­ga­tion­al treat­ments, vac­cines and oth­er tools to fight dis­eases …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER